Infographic: Pivotal clinical trial costs
Clinical trials that support FDA approvals of new drugs have a median cost of $19m – representing less than one percent of the average drug development cost, which is estimated at between $2 and $3bn.
Archives for September 26, 2018
TrialScope debuts website platform with patient engagement capabilities
TrialScope has launched clinical trial transparency service and health literacy management solution.
Certara acquires pharmacometrics modeling workbench, launches BaseCase Portal
The drug development consultancy Certara this week has purchased a pharmacometrics modeling workbench and released a cloud-based platform to allow therapeutic decision-making apps to be delivered at the point of care.
Clinical trial cost is a fraction of the drug development bill, with an average price tag of $19m
The price of running a clinical trial to obtain FDA approval is a fraction of the total drug development cost – challenging traditionally held beliefs about the amount of money required to study prescription drugs, according to new research.
Trials and tribulations: Rare disease research and the shifting care paradigm
As aging populations grow and treatment paradigms shift, the industry must prepare for greater challenges in the rare disease clinical trial space, says CRO executive.
Evonik expands API and advanced intermediates manufacturing with €36m investment
Evonik completed a €36m expansion of its contract manufacturing capabilities of API and advanced intermediates in the US and Europe.
Johnson Matthey offers new synthetic method for ‘ultra-pure’ CBD
The synthetic process produces a crystalline powder that can be particle size-adjusted for formulation requirements, says JM.
Two-thirds of medicines previously unprepared for Brexit now secured
In July, the EMA announced that it had major supply-related concerns for 108 medicines but, two months on, this has dropped to 39.
Ketamine: The future treatment of severe mental illness?
In this first part of a two-part investigation, we look at how NDMA receptor antagonists, such as ketamine, could be poised to make a breakthrough in the treatment of depression – an area where the pharma industry has struggled to identify new targets in...